Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

Both GSK and Pfizer have been selling their holdings in Haleon at a fair clip. This month, Pfizer reduced its holding by 640m shares, selling them for ~$5.1 each for a total value of ~$2.43bn.

Haleon backed its full-year guidance despite ... healthcare business—which was spun out of GSK and is partly owned by Pfizer—said Thursday that revenue for the quarter was 2.78 billion pounds ...

During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of its shares of Haleon, a consumer health joint venture with GSK. In Pfizer's Q3 earnings call ...

In October, Pfizer sold a stake worth about $3.26 billion in British consumer healthcare group Haleon. The moves come at a time when Pfizer, led by Chief Executive Albert Bourla, is facing ...

Bank of America Securities analyst Victoria Petrova has maintained their bullish stance on HLN stock, giving a Buy rating on November 4.

RBC Capital raised the firm’s price target on Haleon (HLN) to 350 GBp from 330 GBp and keeps a Sector Perform rating on the shares.

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...